DMPI Research and Charts

DMPI - DelMar Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-02)

Last 4.11	Change ⇑ +0.02 (+0.49%)	Volume 139,152
	Open 4.10	High 4.27	Low 3.95

8EMA (Daily) 4.30	40EMA (Daily) 4.39	50EMA (Daily) 4.19	STO (Daily) 18.012	MACD Hist (Daily) -0.217
8EMA (Weekly) 4.584	40EMA (Weekly) 2.56	50EMA (Weekly) 2.35	STO (Weekly) 61.274	MACD Hist (Weekly) -0.045


Company Profile
DelMar Pharmaceuticals Inc is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. The company's principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. DelMar also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. All the business activity of the firm is functioned through the region of Canada.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.